Greece Struggles to...
Health Care: Drugs
Threshold Pharmaceuticals Inc. (THLD: NASDAQ)
$3.22 -0.28 | -8.00%
02/09/12 - 04:02 PM ET
1.75M / 130.20K
Vol / Avg. Vol:3.48 / 3.50
Open / Prev. Close:3.17 - 3.53
Today's Range:1.18 - 4.08
52 Wk Range:163.93%
Performance YTD:TheStreet Rating:
Portfolios with THLD
- Portfolio NameUser Type
- ContributorHot Biotech Trades for Seco...
- UserASCO 2010
- UserASCO 2010 Part 2
- UserPART 7 JPMorgan 28th Annual...
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- UserSUPRATRADE NEW-BUY LIST-240...
- UserASCO 2009 Nymph's Watch List.
- UserASCO 2009 Part 2 the end of...
- User#1 bio
Latest THLD Headlines from TheStreet
- 5 Stocks Under $10 Poised for Big Upside 02.03.12 | 02:02 pm
- Biotech Stock Mailbag: Most Important Events for 2012 12.23.11 | 06:12 am
- More Hot Biotech Trades for Second Half 2011 07.12.11 | 06:07 am
- Threshold Pharmaceuticals Reports Fourth Quarter And Year End 2010 Financial Results 03.24.11 | 08:03 am
- Threshold Pharmaceuticals Completes $30 Million Registered Direct Offering 03.17.11 | 08:03 am
- Threshold Pharmaceuticals Announces Registered Direct Offering Of $30 Million 03.11.11 | 09:03 am
- Dean Foods, La-Z Boy: Small-Cap Winners 02.16.11 | 01:02 pm
- Threshold Pharmaceuticals Announces Agreement With The FDA On A Special Protocol Assessment For Planned Phase 3 TH-302 Combination Trial In Advanced Soft Tissue Sarcoma 02.16.11 | 08:02 am
- Threshold Pharmaceuticals' TH-302 Continues To Demonstrate Promising Activity In Pancreatic Cancer Phase 1/2 Clinical Trial 01.24.11 | 08:01 am
- Threshold Pharmaceuticals Announces Promising Early Phase 1 Clinical Trial Results In Patients With Advanced Leukemias 12.22.10 | 08:12 am
Press Releases for THLD
- Threshold Pharmaceuticals Reports Second Quarter 2011 Financial And Operational Results - Business Wire 08.04.11 | 04:08 pm
- Threshold Pharmaceuticals Announces Initiation Of Clinical Trial Evaluating TH-302 In Combination With Bevacizumab At University Of Texas At San Antonio - Business Wire 07.25.11 | 09:07 am
- Threshold Pharmaceuticals Announces National Comprehensive Cancer Network (NCCN) Grant For Phase 1 Trial Of TH-302 In Combination With Pazopanib - Business Wire 07.06.11 | 08:07 am
- Threshold Pharmaceuticals Initiates Clinical Trial Evaluating TH-302 In Combination With Sunitinib - Business Wire 06.29.11 | 06:06 am
- Threshold Pharmaceuticals To Present At OneMedForum Conference - Business Wire 06.22.11 | 06:06 am
- Threshold Pharmaceuticals Announces Completion Of Patient Recruitment For Phase 2 TH-302 Pancreatic Cancer Study - Business Wire 06.21.11 | 04:06 pm
Partner Headlines for THLD
- Benzinga's Microcap Movers for Friday February 3, 2012 - Benzinga 02.05.12 | 11:02 am
- Baker's Dozen Trying To Beat The Odds In Pancreatic Cancer - Seeking Alpha 10.25.11 | 08:10 am
- Low-Priced Biotech Stocks With Insider Buying - Seeking Alpha 03.18.11 | 06:03 pm
- Undervalued Apricus Bio Poised to Follow Threshold Pharma in Receiving SPA Approval - Seeking Alpha 02.17.11 | 09:02 am
- 19 High Growth Micro Cap Stocks Under $10 - Seeking Alpha 01.23.11 | 07:01 am
